Bianchini Massoni Claudio, Perini Paolo, Tecchio Tiziano, Azzarone Matteo, de Troia Alessandro, Freyrie Antonio
Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.
Vascular. 2018 Feb;26(1):90-98. doi: 10.1177/1708538117726468. Epub 2017 Aug 17.
Objectives To collect specific literature on type Ib endoleak after aorto-iliac endografting for abdominal aortic aneurysm, reporting data on diagnosis, treatment, and follow-up results. Methods Publications about type Ib endoleak after aorto-iliac endografting for abdominal aortic or iliac aneurysm were searched in PubMed, Web of Science, and Scopus. Considered studies were in English and published until 3 November 2016. Research methods and reporting were performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Inclusion criteria were: (1) reporting on abdominal aortic or iliac aneurysm as primary diagnosis; (2) reporting on distal endoleak after aorto-iliac endografting. Patient data, data on endovascular treatment, endoleak, reintervention, and follow-up were collected by two independent authors. Results Included studies were 11 (five original articles, six case reports), corresponding to 29 patients and 30 type Ib endoleak. Excluding missing data (2/30, 6.7%), type Ib endoleak was treated intra-operatively, within six months and after six months in six cases (21.4%), eight cases (28.6%), and fourteen cases (50%), respectively. Treatment of type Ib endoleak was endovascular in 27 cases (90%) (7 embolizations + extender cuffs, 10 extender cuffs, 8 embolizations without extender cuff, 1 Palmaz stenting and 1 iliac branched endograft), hybrid in 1 case (3.3%) and surgical in 2 cases (6.6%). Buttock claudication occurred in two cases (6.7%). One-month mortality was 3.4% (2/29) without events due to type Ib endoleak. In 14 cases (46.7%), median follow-up was six months (interquartile range: 2.75-14; range: 0.75-53). Type Ib endoleak persisted or reappeared in three cases (10%), all after endovascular treatment. Two of these (2/3, 66.7%) needed endovascular reintervention. No death during follow-up was reported. Conclusions Few specific data are available in literature about type Ib endoleak after aorto-iliac endografting for abdominal aortic aneurysm. About 50% of type Ib endoleak occurred after six months from the endovascular abdominal aneurysm repair procedure. Treatment is mainly endovascular and distal endograft extension is the main and effective treatment. Buttock claudication is the most frequent complication in case of exclusion of internal iliac artery. Persistent type Ib endoleak is possible, and adjunctive endovascular procedures are necessary.
收集腹主动脉瘤髂股动脉内植入术后Ib型内漏的相关特定文献,报告诊断、治疗及随访结果的数据。方法:在PubMed、科学网和Scopus数据库中检索关于腹主动脉或髂动脉瘤髂股动脉内植入术后Ib型内漏的出版物。纳入的研究需为英文且发表时间截至2016年11月3日。研究方法和报告遵循系统评价与Meta分析的首选报告项目(PRISMA)声明。纳入标准为:(1)以腹主动脉或髂动脉瘤作为主要诊断进行报告;(2)报告髂股动脉内植入术后的远端内漏。由两名独立作者收集患者数据、血管内治疗数据、内漏情况、再次干预及随访数据。结果:纳入的研究共11项(5篇原创文章,6篇病例报告),涉及29例患者和30例Ib型内漏。排除缺失数据(2/30,6.7%)后,Ib型内漏分别在术中、术后6个月内及6个月后进行治疗的病例数为6例(21.4%)、8例(28.6%)和14例(50%)。Ib型内漏的治疗方式中,27例(90%)为血管内治疗(7例栓塞联合延长袖套,10例延长袖套,8例无延长袖套的栓塞,1例Palmaz支架置入和1例髂支型血管内移植物),1例(3.3%)为杂交治疗,2例(6.6%)为手术治疗。2例(6.7%)出现臀部间歇性跛行。1个月死亡率为3.4%(2/29),无因Ib型内漏导致的死亡事件。14例(46.7%)患者的中位随访时间为6个月(四分位间距:2.75 - 14;范围:0.75 - 53)。3例(10%)患者的Ib型内漏持续存在或复发,均发生在血管内治疗后。其中2例(2/3,66.7%)需要再次进行血管内干预。随访期间未报告死亡病例。结论:关于腹主动脉瘤髂股动脉内植入术后Ib型内漏的文献中特定数据较少。约50%的Ib型内漏发生在血管内腹主动脉瘤修复术后6个月。治疗主要为血管内治疗,远端血管内移植物延长是主要且有效的治疗方法。排除髂内动脉时,臀部间歇性跛行是最常见的并发症。Ib型内漏可能持续存在,需要辅助血管内治疗。